CN110464007A - 具有利肾、抗衰老功能的保健饮料配方及其制备方法 - Google Patents
具有利肾、抗衰老功能的保健饮料配方及其制备方法 Download PDFInfo
- Publication number
- CN110464007A CN110464007A CN201810436443.3A CN201810436443A CN110464007A CN 110464007 A CN110464007 A CN 110464007A CN 201810436443 A CN201810436443 A CN 201810436443A CN 110464007 A CN110464007 A CN 110464007A
- Authority
- CN
- China
- Prior art keywords
- parts
- juice
- kidney
- extract
- sweetener
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003734 kidney Anatomy 0.000 title claims abstract description 50
- 235000013361 beverage Nutrition 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000036541 health Effects 0.000 title claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 50
- 240000007228 Mangifera indica Species 0.000 claims abstract description 43
- 235000014826 Mangifera indica Nutrition 0.000 claims abstract description 43
- 235000004936 Bromus mango Nutrition 0.000 claims abstract description 42
- 235000009184 Spondias indica Nutrition 0.000 claims abstract description 42
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 32
- 239000003765 sweetening agent Substances 0.000 claims abstract description 32
- 239000002994 raw material Substances 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 11
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 7
- 244000036978 Caesalpinia bonduc Species 0.000 claims abstract 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 45
- 235000006647 Eugenia jambos Nutrition 0.000 claims description 30
- 244000087016 Syzygium jambos Species 0.000 claims description 30
- 230000032683 aging Effects 0.000 claims description 30
- 235000015203 fruit juice Nutrition 0.000 claims description 28
- 241000427324 Glinus Species 0.000 claims description 25
- 230000006870 function Effects 0.000 claims description 25
- 238000005303 weighing Methods 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 24
- 230000001954 sterilising effect Effects 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 19
- 235000007627 Caesalpinia Nutrition 0.000 claims description 15
- 241000522234 Caesalpinia Species 0.000 claims description 15
- 235000016513 Caesalpinia crista Nutrition 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 10
- 235000014145 Caesalpinia bonduc Nutrition 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 8
- 239000012043 crude product Substances 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- 235000021552 granulated sugar Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- 235000006481 Colocasia esculenta Nutrition 0.000 claims description 6
- 244000205754 Colocasia esculenta Species 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 235000013944 peach juice Nutrition 0.000 claims description 4
- 235000009133 Caesalpinia coriaria Nutrition 0.000 claims 1
- 235000005082 Caesalpinia paraguariensis Nutrition 0.000 claims 1
- 241001618206 Libidibia coriaria Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 239000003814 drug Substances 0.000 abstract description 19
- 108020004999 messenger RNA Proteins 0.000 abstract description 10
- 210000000582 semen Anatomy 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000035622 drinking Effects 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 239000006188 syrup Substances 0.000 abstract 1
- 235000020357 syrup Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 25
- 238000010992 reflux Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 108050004036 Klotho Proteins 0.000 description 17
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 description 13
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 13
- 102000015834 Klotho Human genes 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 12
- 244000296749 Caesalpinia crista Species 0.000 description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 108010012715 Superoxide dismutase Proteins 0.000 description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000002791 soaking Methods 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000005084 renal tissue Anatomy 0.000 description 5
- 210000005239 tubule Anatomy 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000010094 cellular senescence Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009103 reabsorption Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 241000245665 Taraxacum Species 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000012856 weighed raw material Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- RIXNFYQZWDGQAE-DFHVBEEKSA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C([C@H]1C2=CC[C@H]34)C(C)(C)CC[C@]1(C(O)=O)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C RIXNFYQZWDGQAE-DFHVBEEKSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 244000234162 Eugenia cumini Species 0.000 description 2
- 235000012097 Eugenia cumini Nutrition 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960005084 calcitriol Drugs 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 150000004141 diterpene derivatives Chemical class 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000000231 kidney cortex Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- -1 m-digallic acid methyl ester Chemical class 0.000 description 2
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 2
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- JDRMYOQETPMYQX-UHFFFAOYSA-N monomethyl succinate Chemical compound COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
- 102000034534 Cotransporters Human genes 0.000 description 1
- 108020003264 Cotransporters Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101150104085 Cyp24a1 gene Proteins 0.000 description 1
- 101150099181 Cyp27b1 gene Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920002707 Digallic acid Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004262 Ethyl gallate Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 241000235503 Glomus Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000009220 Liuwei Dihuang Decoction Substances 0.000 description 1
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000388430 Tara Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HEAFLBOWLRRIHV-UHFFFAOYSA-N [Na].[P] Chemical compound [Na].[P] HEAFLBOWLRRIHV-UHFFFAOYSA-N 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- COVFEVWNJUOYRL-UHFFFAOYSA-N dehydrodigallic acid Natural products OC(=O)C1=CC(O)=C(O)C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 COVFEVWNJUOYRL-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019277 ethyl gallate Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000001795 light effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- DMFPEGLBGOENBN-UHFFFAOYSA-N m-Digallic acid Natural products Cc1c(O)cc(cc1OC(=O)c2cc(O)c(O)c(O)c2)C(=O)O DMFPEGLBGOENBN-UHFFFAOYSA-N 0.000 description 1
- 229940043357 mangiferin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/72—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有利肾、抗衰老功能的保健饮料配方,其包括如下重量份的组分:芒果核提取物1‑20份,蒲桃提取物2‑20份,大托叶云实提取物2‑20份,甜味剂1‑10份,水果汁1‑5份,加水至100份。本发明的优点在于,芒果核、蒲桃、大托叶云实为药食两用果实类蒙药,为药食同源的药材,在蒙医临床运用数千年,在利肾、滋补方面疗效确切,本发明制得的保健饮料,通过显著上调klotho基因mRNA表达水平,增强抗衰老效果及利肾效果,经常食用可滋补肾脏、延缓衰老,填补了市面上此方面产品的空白;本发明的制备方法工序简单、科学合理,不会破坏原料中的有效成分,适用于工业化生产。
Description
技术领域:
本发明涉及一种饮料配方及其制备方法,特别涉及一种具有利 肾、抗衰老功能的保健饮料配方及其制备方法。
背景技术:
衰老是一种普遍存在于生物系统中的退行性过程,伴随着不可逆 的退行性变化积累和不断增加的疾病敏感性,并最终造成死亡。因人 体是由细胞构成,细胞衰老构成了机体的衰老。与细胞衰老最为相关 的是氧化应激(ROS),它作为细胞衰老的上游信号直接损伤DNA并引 起细胞的衰老;也可以直接调控衰老相关信号通路,引起衰老。氧化 应激不仅可以引起细胞的衰老,它的副产物O2-、H2O2和OH-等也可直 接损伤构成细胞的结构或组织,造成机体组织器官的进一步衰老。
近年来研究发现,氧化应激是导致肾脏损伤的主要病理过程之 一。体内和体外试验中均发现,klotho蛋白能够抑制氧化应激反应, 具有klotho基因缺陷的小鼠体内氧化应激明显增高。在氧化应激的 情况下,klotho基因表达的klotho蛋白的表达水平下降,而清除氧 自由基的抗氧化治疗则可以抑制klotho蛋白的下降。klotho转基因 小鼠发生肾小球肾炎时,其肾功能和形态学损害则比较轻,细胞色素 C氧化反应获得改善,B半乳糖普酶(一种衰老蛋白)的活性、线粒体 DNA的裂解、超氧阴离子的产生、脂质过氧化、Bax蛋白的表达及凋 亡均表现为显著降低。这种改善不仅见于肾小管还见于肾小球,以此 证实了klotho蛋白能够通过作为循环激素,减轻线粒体的氧化应激 来发挥显著的肾脏保护作用。
FGF-23是新近发现的血鳞调节因子,由骨细胞分泌,通过骨-内 分泌轴发挥作用,其主要通过两种途径作用于肾脏:(1)80%磷酸盐的 重吸收发生在肾脏近曲小管,而FGF-23可通过抑制近曲小管上皮细 胞膜刷状缘上的钠-磷协同转运蛋白Ⅱ(Na/PiⅡa及Na/PiⅡc),进而 抑制磷酸盐的重吸收,从而增加尿中磷酸盐的排泄,达到维持血磷平 衡的作用;(2)1-羟基酶(Cyp27b1)和24-羟基酶(Cyp24a1)分别为肾 脏合成和分解活性1,25(OH)2D3(1,25-二羟维生素D3)所需要的酶, FGF-23下调1-羟基酶,上调24-羟基酶在肾脏近曲小管的表达,从 而降低活性1,25(OH)2D3的合成,下调1,25(OH)2D3能减少磷从小 肠中的吸收,故FGF-23的主要功能是下调血清磷的水平。
研究发现,新的肾-骨内分泌轴,由肾小管产生的klotho蛋白 与骨骼分泌的FGF-23组成,共同调节维生素D及钙磷代谢。生理情 况下,klotho-FGF-23轴通过抑制肾小管对磷的重吸收,促进尿磷酸 盐的排泄,还可抑制1-羟化酶活性,导致骨化三醇减少,进而减少肠道对磷钙的重吸收。而在病理情况下,肾脏分泌klotho蛋白明显 减少,机体呈现对FGF-23抵抗状态,FGF-23失去对骨矿物代谢的有 效调节,致使血磷升高,继发性甲状旁腺功能亢进,维生素D缺乏, 最终导致骨矿物质代谢的整体失衡。高钙磷刺激血管内皮细胞发现PKC活化,NADPH氧化酶活性增加,ROS产生增加,NO合酶活性NO下 降生成减少,结果证明高憐可导致血管内皮受损,使血管内皮功能障 碍,机体氧化应激反应放大,血管钙化,导致机体衰老。
蒙医学认为,人体是以各种因素相互依赖,相互制约,保持平衡 关系的有机体,由于各种外因的影响,使体内“三根七素”的平衡失 调互相拮抗发生一系列异常关系,就是人体患病的主要因素,即致病 机理。三根为:赫伊、希拉、巴达干。七素为:饮食津液、血、肉、脂肪、骨、骨髓、精液(精液为白、红两种)等七种。七素中的饮食津 液尤为重要,因为其它六种物质均由津液转变而成。这六种物质中的 脂肪能柔润身体、悦气色;骨能支架人体;骨髓能生精;而精液的功 能是生殖繁衍后代。骨髓在肾功能下转变为精液,精液之津液为精华。精华分布身体各处,功能为悦气色、延缓衰老。
综上所述,一旦肾脏出现损伤或发生病变,肾功能降低,则可直 接导致机体的衰老,加速机体衰老。而目前,市面上未见可以利肾、 抗衰老的保健产品,亟需开发可以利肾、抗衰老的保健产品填补市面 上的空白。
发明内容:
本发明的第一个目的在于提供一种延缓衰老、滋补肾脏的具有利 肾、抗衰老功能的保健饮料配方。
本发明的第二个目的在于提供一种工序简单、科学合理的具有利 肾、抗衰老功能的保健饮料的制备方法。
本发明的第一个目的由如下技术方案实施:具有利肾、抗衰老功 能的保健饮料配方,其包括如下重量份的组分:芒果核提取物1-20 份,蒲桃提取物2-20份,大托叶云实提取物2-20份,甜味剂1-10 份,水果汁1-5份,加水至100份。
进一步的,所述甜味剂为白砂糖或木糖醇中的任意一种。
进一步的,所述水果汁为芒果汁、蒲桃汁或大托叶云实汁中的任 意一种。
上述各成分功效如下:
芒果核,蒙药名为芒果日-吉木斯,为漆树科植物芒果Mangifera indica L.的干燥成熟种子。味甘、酸,性温,效重、腻。具有补肾、 祛肾寒之功效,主要用于肾虚、肾寒、腰腿痛等。芒果核含有表儿茶 素、没食子酸、没食子酸乙酯、间-二没食子酸甲酯、对羟基苯甲酸、 丁二酸单甲酯、没食子酸甲酯、咖啡酸、阿魏酸、鞣花酸、香豆素, 熊果苷、香兰素、β-谷甾醇等化学成分外,尚含有维生素A、维生 素C、糖、蛋白质、钙、磷、铁等人体所必需的营养成分。具有免疫 调节作用、调节糖脂代谢、抗氧化、抗炎、抗病毒、抑菌、抗肿瘤、 降血糖等多种药理作用;其提取物对标准和耐药志贺痢疾杆菌、福氏 痢疾杆菌、大肠杆菌有不同程度体外抑菌作用;
蒲桃,蒙药名为恰黑日各-乌热,为桃金娘科常绿乔木海南蒲桃 Syzygium cumini(L.)Skeels的干燥成熟果实。味甘、涩,性温, 效轻。具有补肾、祛“八达干”寒之功效,主要用于淋病、遗精、腰 腿疼、游痛症、闭尿、石痞、肾阳不足等。蒲桃含有丰富的乙酰齐墩 果酸、三萜类、鞣质、精油、花青素、黄酮和酚类成分等具有药用与 保健功能的多种成分外,尚含有碳水化合物、蛋白质、脂肪、纤维素 及钙、磷、铁等多种植物组织常见物质。具有抗炎、抗氧化、抗过敏、 抗糖尿病、调血压、抗溃疡、保护胃肠道等重要的药用价值。同时, 蒲桃中的原花青素具有较强的清除自由基与抗氧化活性等体外活性;
大托叶云实,蒙药名为卓楞-乌热,为豆科植物大托叶云实 Caesalpinia cristaL.的干燥成熟种子。味辛、涩,性温。具有暖 胃、温肾、补肾之功效,主要用于肾寒、腰腿痛、尿频、遗精、尿闭、 石痞、胃寒症等。大托叶云实现代研究报道很少,主要集中在其所含 二萜类成分及其抗疟疾作用方面。根据《蒙药学》记载,大托叶云实 含有甾醇、皂苷、脂肪油、淀粉和多种苦味素。其苦味素和醇提取物 降血压和抑制心脏作用,苦味素尚有抑菌、杀虫等活性;
本发明的第二个目的由如下技术方案实施:具有利肾、抗衰老功 能的保健饮料制备方法,其包括如下步骤:(1)称取原料,(2)制备 甜味汁,(3)调配,(4)均质,(5)杀毒;其中,
所述(1)称取原料:称取如下重量份的原料:芒果核提取物1-20 份,蒲桃提取物2-20份,大托叶云实提取物2-20份,水果汁1-5份; 之后将其混合成原汁;
所述(2)制备甜味汁:所述(1)称取原料完成后,称取重量份 为1-10份的甜味剂,将称取好的所述甜味剂加入70-80℃的水中充 分溶解,在110-121℃进行杀菌处理,冷却至10-20℃,得到甜味汁;
所述(3)调配:所述(2)制备甜味汁完成后,将所述原汁与所 述甜味汁混合,搅拌均匀并加水定容至100份重量份,得到粗成品;
所述(4)均质:所述(3)调配完成后,将所述粗成品在压力为 20-25MPa、温度为51-54℃的条件下进行均质,均质时间为10-30min, 得到均质成品;
所述(5)杀毒:所述(4)均质完成后,将所述均质成品在温度 为95-98℃的条件下杀菌20-30min,冷却至10-20℃,即得饮料成品。
进一步的,所述甜味剂为白砂糖或木糖醇中的任意一种。
进一步的,所述水果汁为芒果汁、蒲桃汁或大托叶云实汁中的任 意一种或几种的组合。
进一步的,所述水果汁的制备方法如下:将水果清洗干净,然后 将清洗后的所述水果在转速为2000-3000r/min的条件下搅拌 5-10min,得到榨汁,所述榨汁用200目过滤网过滤两次,得到所述 水果汁。以上各成分功效如下:
本发明的优点:1、芒果核、蒲桃、大托叶云实为药食两用果实 类蒙药,为药食同源的药材,在蒙医临床运用数千年,在利肾、滋补 方面疗效确切,本发明制得的保健饮料,通过显著上调klotho基因 mRNA表达水平,增强抗衰老效果及利肾效果,经常食用可滋补肾脏、 延缓衰老,填补了市面上此方面产品的空白;2、本发明的制备方法 工序简单、科学合理,不会破坏原料中的有效成分,适用于工业化生 产。
具体实施方式:
实施例1:
具有利肾、抗衰老功能的保健饮料配方,其包括如下重量份的组 分:芒果核提取物1份,蒲桃提取物2份,大托叶云实提取物2份, 甜味剂1份,水果汁1份,加水至100份。甜味剂为白砂糖;水果汁 为芒果汁。
其中,芒果核提取物、蒲桃提取物、大托叶云实提取物由如下制 备方法制得:(1)称取芒果核、蒲桃或大托叶云实1000g用蒸馏水清 洗三遍;(2)在洗净的5000ml的烧瓶中加2500ml、75%乙醇,把洗 净的芒果核、蒲桃或大托叶云实放入烧瓶中,常温浸泡三天,分离得 到浸泡液;(3)将浸泡液置于5000ml圆底烧瓶中利用旋转蒸发仪进 行回流提取,沸腾2h后分离得到回流液,将回流液置于旋转蒸发器 中进行旋转蒸发,至回流液浓缩汁原体积的1/10,得到浓缩回流液; (4)将浓缩回流液进行冷冻干燥,冷冻干燥温度为-70℃,冷冻干燥时间为24h,冷冻干燥产物即为对应原料的提取物,将提取物装入封 口袋中,-4°储存,待使用。
甜味剂用于调节饮料的甜度,在本实施例中甜味剂为白砂糖;
水果汁用于调节饮料的口感,在本实施例中水果汁为芒果汁,芒 果汁能增加胃肠蠕动,芒果中的含有芒果苷,有明显的抗脂质过氧化 和保护脑神经元的作用,能延缓细胞衰老、提高脑功能。芒果汁中的 芒果果肉具有祛痰、止咳、抗癌、润泽皮肤的药理作用。
上述配方通过以下制备方法实施,具有利肾、抗衰老功能的保健 饮料制备方法,其包括如下步骤:(1)称取原料,(2)制备甜味汁, (3)调配,(4)均质,(5)杀毒;其中,
(1)称取原料:称取如下重量份的原料:芒果核提取物1份, 蒲桃提取物2份,大托叶云实提取物2份,水果汁1份;在本实施例 中,水果汁为芒果汁;芒果汁的制备方法如下:现将芒果清洗干净, 然后清洗后的芒果在转速为2000r/min搅拌5min,得到榨汁,榨汁 用200目过滤网过滤两次过,得到芒果汁。
(2)制备甜味汁:(1)称取原料完成后,称取重量份为1份的 甜味剂,将称取好的甜味剂加入70℃的水中充分溶解,在110℃条件 下进行杀菌处理,冷却至10℃,得到甜味汁;在本实施例中,甜味 剂为白砂糖。
(3)调配:(2)制备甜味汁完成后,将称取好的原料与甜味汁 混合,搅拌均匀并加水定容至100份,得到粗成品。
(4)均质:(3)调配完成后,将粗成品在压力为20MPa、温度 为51℃的条件下进行均质,均质时间为10分钟,得到均质成品。
(5)杀毒:(4)均质完成后,将均质成品在温度为95℃的条件 下杀菌20min,冷却至10℃,即得饮料成品。
实施例2:
具有利肾、抗衰老功能的保健饮料配方,其包括如下重量份的组 分:芒果核提取物10份,蒲桃提取物10份,大托叶云实提取物10 份,甜味剂5份,水果汁3份,加水至100份。甜味剂为木糖醇;水 果汁为蒲桃汁。
其中,芒果核提取物、蒲桃提取物、大托叶云实提取物由如下制 备方法制得:(1)称取芒果核、蒲桃或大托叶云实1000g用蒸馏水清 洗三遍;(2)在洗净的5000ml的烧瓶中加2500ml、75%乙醇,把洗 净的芒果核、蒲桃或大托叶云实放入烧瓶中,常温浸泡三天,分离得 到浸泡液;(3)将浸泡液置于5000ml圆底烧瓶中利用旋转蒸发仪进 行回流提取,沸腾2h后分离得到回流液,将回流液置于旋转蒸发器 中进行旋转蒸发,至回流液浓缩汁原体积的1/10,得到浓缩回流液; (4)将浓缩回流液进行冷冻干燥,冷冻干燥温度为-70℃,冷冻干燥时间为24h,冷冻干燥产物即为对应原料的提取物,将提取物装入封 口袋中,-4°储存,待使用。
甜味剂用于调节饮料的甜度,在本实施例中甜味剂为木糖醇,方 便患有糖尿病或不适用摄取蔗糖的人群食用;
水果汁用于调节饮料的口感,在本实施例中水果汁为蒲桃汁。
上述配方通过以下制备方法实施,具有利肾、抗衰老功能的保健 饮料制备方法,其包括如下步骤:(1)称取原料,(2)制备甜味汁, (3)调配,(4)均质,(5)杀毒;其中,
(1)称取原料:称取如下重量份的原料:芒果核提取物10份, 蒲桃提取物10份,大托叶云实提取物10份,水果汁3份;在本实施 例中,水果汁为蒲桃汁。蒲桃汁的制备方法如下:现将蒲桃清洗干净, 然后清洗后的蒲桃在转速为2500r/min搅拌8min,得到榨汁,榨汁用200目过滤网过滤两次过,得到蒲桃汁。
(2)制备甜味汁:(1)称取原料完成后,称取重量份为5份的 甜味剂,将称取好的甜味剂加入75℃的水中充分溶解,在120℃条件 下进行杀菌处理,冷却至15℃,得到甜味汁;在本实施例中,甜味 剂为木糖醇,方便患有糖尿病或不适用摄取蔗糖的人群食用。
(3)调配:(2)制备甜味汁完成后,将称取好的原料与甜味汁 混合,搅拌均匀并加水定容至100份,得到粗成品。
(4)均质:(3)调配完成后,将粗成品在压力为23MPa、温度 为52℃的条件下进行均质,均质时间为15分钟,得到均质成品。
(5)杀毒:(4)均质完成后,将均质成品在温度为96℃的条件 下杀菌25min,冷却至15℃,即得饮料成品。
实施例3:
具有利肾、抗衰老功能的保健饮料配方,其包括如下重量份的组 分:芒果核提取物20份,蒲桃提取物20份,大托叶云实提取物20 份,甜味剂10份,水果汁5份,加水至100份。甜味剂为白砂糖, 水果汁为芒果汁。
其中,芒果核提取物、蒲桃提取物、大托叶云实提取物由如下制 备方法制得:(1)称取芒果核、蒲桃或大托叶云实1000g用蒸馏水清 洗三遍;(2)在洗净的5000ml的烧瓶中加2500ml、75%乙醇,把洗 净的芒果核、蒲桃或大托叶云实放入烧瓶中,常温浸泡三天,分离得 到浸泡液;(3)将浸泡液置于5000ml圆底烧瓶中利用旋转蒸发仪进 行回流提取,沸腾2h后分离得到回流液,将回流液置于旋转蒸发器 中进行旋转蒸发,至回流液浓缩汁原体积的1/10,得到浓缩回流液; (4)将浓缩回流液进行冷冻干燥,冷冻干燥温度为-70℃,冷冻干燥时间为24h,冷冻干燥产物即为对应原料的提取物,将提取物装入封 口袋中,-4°储存,待使用。
甜味剂用于调节饮料的甜度,在本实施例中甜味剂为白砂糖;
水果汁用于调节饮料的口感,在本实施例中水果汁为芒果汁和大 托叶云实汁。
上述配方通过以下制备方法实施,具有利肾、抗衰老功能的保健 饮料制备方法,其包括如下步骤:(1)称取原料,(2)制备甜味汁, (3)调配,(4)均质,(5)杀毒;其中,
(1)称取原料:称取如下重量份的原料:芒果核提取物20份, 蒲桃提取物20份,大托叶云实提取物20份,水果汁5份;在本实施 例中,水果汁为大托叶云实汁。蒲桃汁的制备方法如下:现将大托叶 云实清洗干净,然后清洗后的大托叶云实在转速为3000r/min搅拌10min,得到榨汁,榨汁用200目过滤网过滤两次过,得到大托叶云 实汁。
(2)制备甜味汁:(1)称取原料完成后,称取重量份为10份的 甜味剂,将称取好的甜味剂加入80℃的水中充分溶解,在121℃条件 下进行杀菌处理,冷却至20℃,得到甜味汁;在本实施例中,甜味 剂为白砂糖。
(3)调配:(2)制备甜味汁完成后,将称取好的原料与甜味汁 混合,搅拌均匀并加水定容至100份,得到粗成品。
(4)均质:(3)调配完成后,将粗成品在压力为25MPa、温度 为54℃的条件下进行均质,均质时间为30分钟,得到均质成品。
(5)杀毒:(4)均质完成后,将均质成品在温度为98℃的条件 下杀菌30min,冷却至20℃,即得饮料成品。
实施例4:
一、分组设计
选择大鼠(Wistar大鼠,购自湖北省实验动物研究中心)共40 只,分为4组,每组10只;分别命名为模型组、蒙药组、阳性对照 组和正常组。
二、给药及饲喂方法
模型组、蒙药组、阳性对照组的大鼠每天每只腹腔注射D-半乳 糖0.1g/kg,正常组大鼠每天每只腹腔注射等计量生理盐水。四组大 鼠置于同样的环境下饲养,除每日正常饲食给水外,各组还包括如下 处理方法:
模型组:取400mL超纯水置于饲喂笼内,自由取食,每日更换一 次;
蒙药组:取本发明实施例1的饮料成品100mL,用超纯水稀释至 800mL,取400mL置于饲喂笼内,自由取食,每日更换一次;
阳性对照组:取六味地黄丸3g,用800mL超纯水溶解,取400mL 置于饲喂笼内,自由取食,每日更换一次;
正常组:取400mL超纯水置于饲喂笼内,自由取食,每日更换一 次。
三、大鼠处理方法及检验结果
1、造模验证
模型组与正常组大鼠,观测饲喂40d后各组肾脏MDA和SOD的含 量,如表1所示;以及检测造模前、造模28天、造模40天时的体重, 观察体重增长率,如表2所示。
表1两组大鼠肾脏MDA及SOD指标检测(x±s)
正常组与模型组相比,P<0.01
表2两组各组大鼠体重检测(х±s)
正常组与模型组相比,P<0.01
由表1、表2及统计学分析可知,正常组与模型组大鼠相比,正 常组大鼠血清中的SOD活性显著降低,MDA含量显著升高,肾脏出现 衰老的表现,表明模型建立成功。
2、抗衰老效果
造模8周后颈椎脱位术处死裸鼠,分别取各组大鼠肾脏组织进行 匀浆,并观测肾组织匀浆中血清超氧化物歧化酶(SOD)活性、MDA蛋 白含量及FGF-23蛋白的变化,结果如表3所示;
表3各组大鼠肾组织匀浆中SOD、MDA、FGF-23变化
蒙药组与正常组相比,P<0.05;蒙药组与模型组相比,P<0.01。
由表3可知,与正常组相比,蒙药组大鼠肾脏组织中SOD活性、 MDA蛋白含量及FGF-23蛋白含量均具有显著差别;与模型组相比, 蒙药组大鼠肾脏组织中SOD活性、MDA蛋白含量及FGF-23蛋白含量 均具有极显著差别;即随着年龄的增长,大鼠肾脏出现衰老的表现,SOD活性降低,MDA含量升高,对抗自由基能力下降,脂质过氧化的 产物增加,细胞DNA受到损伤,而给大鼠喂养本发明后,大鼠体内 FGF-23蛋白表达量增加,并进一步影响肾脏中SOD及MDA的含量, 从而改善衰老的表现。
3、基因水平验证
上述8周后颈椎脱位术处死裸鼠,取各组颈椎脱位术处死裸鼠的 肾脏皮质,提取总RNA,定量。利用RT-PCR技术,检测klotho基因 mRNA的表达水平。
引物设计如下:
A、Klotuo:两个引物之间碱基数在300bp左右。
上游引物5′-AGGAAACCGAGGCAGAGG-3′,
下游引物5-ACACGGGAAGCCAAGGAG-3′。
内参β-actin:扩增片段长度为564bp。
上游引物:5′-CTG GGA CGA CAT GGA GAA AA-3′,
下游引物:5′-AAG GAA GGC TGG AAG AGT GC-3′,
PCR反应条件为:95℃预变性5min;95℃30s,56℃30s,70℃ 30s,35个循环;72℃延伸10min。结果用Quantity One 4.6.2 软件进行分析。上述操作每组设三组平行试验,结果如表4所示:
表4各组mRNA表达水平
对表4数据进行统计学分析可知,模型组大鼠肾脏皮质Klotho mRNA表达与正常组比较明显下降(P<0.01),阳性对照组大鼠肾脏皮质 Klotho mRNA表达与正常组比较下降(P<0.05);蒙药组大鼠肾脏皮质 Klotho mRNA表达与正常组比较无明显差异(P>0.05);蒙药组与模型 组相比较,大鼠肾脏皮质Klotho mRNA表达明显增强(P<0.01),蒙药 组与阳性对照组比较,大鼠肾脏皮质klotho mRNA增强(P<0.05)。即 本发明饲喂大鼠后,大鼠肾脏皮质klotho mRNA表达水平有显著的上 调作用。
综上所述,本发明可通过显著上调klotho基因mRNA表达水平, 提高FGF-23的含量,进而增强抗衰老效果及利肾效果,经常食用可 滋补肾脏、延缓衰老,填补了市面上此方面产品的空白。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明, 凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等, 均应包含在本发明的保护范围之内。
Claims (7)
1.具有利肾、抗衰老功能的保健饮料配方,其特征在于,其包括如下重量份的组分:芒果核提取物1-20份,蒲桃提取物2-20份,大托叶云实提取物2-20份,甜味剂1-10份,水果汁1-5份,加水至100份。
2.根据权利要求1所述的具有利肾、抗衰老功能的保健饮料配方,其特征在于,所述甜味剂为白砂糖或木糖醇中的任意一种。
3.根据权利要求1或2任一所述的具有利肾、抗衰老功能的保健饮料配方,其特征在于,所述水果汁为芒果汁、蒲桃汁或大托叶云实汁中的任意一种。
4.具有利肾、抗衰老功能的保健饮料制备方法,其特征在于,其包括如下步骤:(1)称取原料,(2)制备甜味汁,(3)调配,(4)均质,(5)杀毒;其中,
所述(1)称取原料:称取如下重量份的原料:芒果核提取物1-20份,蒲桃提取物2-20份,大托叶云实提取物2-20份,水果汁1-5份;之后将其混合成原汁;
所述(2)制备甜味汁:所述(1)称取原料完成后,称取重量份为1-10份的甜味剂,将称取好的所述甜味剂加入70-80℃的水中充分溶解,在110-121℃进行杀菌处理,冷却至10-20℃,得到甜味汁;
所述(3)调配:所述(2)制备甜味汁完成后,将所述原汁与所述甜味汁混合,搅拌均匀并加水定容至100份重量份,得到粗成品;
所述(4)均质:所述(3)调配完成后,将所述粗成品在压力为20-25MPa、温度为51-54℃的条件下进行均质,均质时间为10-30min,得到均质成品;
所述(5)杀毒:所述(4)均质完成后,将所述均质成品在温度为95-98℃的条件下杀菌20-30min,冷却至10-20℃,即得饮料成品。
5.根据权利要求4所述的具有利肾、抗衰老功能的保健饮料制备方法,其特征在于,所述甜味剂为白砂糖或木糖醇中的任意一种。
6.根据权利要求4或5任一所述的具有利肾、抗衰老功能的保健饮料制备方法,其特征在于,所述水果汁为芒果汁、蒲桃汁或大托叶云实汁中的任意一种或几种的组合。
7.根据权利要求6所述的具有利肾、抗衰老功能的保健饮料制备方法,其特征在于,所述水果汁的制备方法如下:将水果清洗干净,然后将清洗后的所述水果在转速为2000-3000r/min的条件下搅拌5-10min,得到榨汁,所述榨汁用200目过滤网过滤两次,得到所述水果汁。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810436443.3A CN110464007A (zh) | 2018-05-09 | 2018-05-09 | 具有利肾、抗衰老功能的保健饮料配方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810436443.3A CN110464007A (zh) | 2018-05-09 | 2018-05-09 | 具有利肾、抗衰老功能的保健饮料配方及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110464007A true CN110464007A (zh) | 2019-11-19 |
Family
ID=68503354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810436443.3A Withdrawn CN110464007A (zh) | 2018-05-09 | 2018-05-09 | 具有利肾、抗衰老功能的保健饮料配方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110464007A (zh) |
-
2018
- 2018-05-09 CN CN201810436443.3A patent/CN110464007A/zh not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101277710B (zh) | 减肥组成物 | |
Ali et al. | 26 Nutritional and Medicinal Value of Date Fruit | |
CN101253903B (zh) | 一种具有减肥功能的保健食品及其制备方法 | |
CN101579120A (zh) | 一种具有减肥功能的营养食品及其制备方法 | |
US20130018009A1 (en) | Anti-obesity product and its method of preparation | |
Zhao et al. | Polygonati Rhizoma with the homology of medicine and food: A review of ethnopharmacology, botany, phytochemistry, pharmacology and applications | |
CN106562428A (zh) | 一种美颜美体膏滋及其制备方法 | |
JP4937445B2 (ja) | 骨代謝改善剤及び骨粗鬆症の予防又は治療用飲食物 | |
CN102526360B (zh) | 一种具有辅助减肥功能的保健品 | |
EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
CN110269251A (zh) | 一种通便促排的组合物及其制备方法 | |
JP4993817B2 (ja) | 骨代謝改善剤及び骨粗鬆症の予防又は治療用飲食物 | |
CN102499300A (zh) | 一种具有抗氧化功效的固体茶及其制备方法 | |
CN110464007A (zh) | 具有利肾、抗衰老功能的保健饮料配方及其制备方法 | |
AU2010205126B2 (en) | Postprandial hyperglycemia-improving agent | |
CN104887759A (zh) | 一种人参粉酒及其制备方法 | |
CN113875864A (zh) | 一种降血糖抑糖茶及其制备方法 | |
CN103181557A (zh) | 具有减肥功能的营养食品及其制备方法 | |
KR101391647B1 (ko) | 항비만 조성물 | |
Patel et al. | A review on flax seed: A legume for longevity | |
CN111903822A (zh) | 一种补钙成长型夹心凝胶糖果及其制备方法 | |
KR101930145B1 (ko) | 절식 보조용 조성물 | |
CN104186749A (zh) | 一种降低三高的保健奶茶及其制备方法 | |
Kurniawati et al. | Potential of Mangosteen Peel Extract Jelly Candy (Garcinia mangoestana L) To Control The Blood Glucose Level in Diabetes Mellitus Patients | |
KR102517948B1 (ko) | 복방 한방 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191119 |
|
WW01 | Invention patent application withdrawn after publication |